Neuroendocrine Tumor

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

Potential Survival Advantage Observed for 177Lu-Dotatate in Midgut Neuroendocrine Tumors

By

NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.

Targeted Hormone-radiation Treatment Shows Promise in Midgut Neuroendocrine Tumors

By

Tumor growth may be substantially slowed by the novel therapy 177Lutetium-DOTATATE (Lutathera), according to early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors.

Progression-free Survival of Patients With Neuroendocrine Tumors Improved With Everolimus

By

A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.

Neuroendocrine cancer halted by chemo-radionuclide therapy

By

Advanced cancer of the neuroendocrine system can lead to dismal prognoses, but a novel therapy is packing a punch by uniting powerful radionuclide treatment and chemotherapy drugs.

Chemo combo promising for pancreatic neuroendocrine tumors

Chemo combo promising for pancreatic neuroendocrine tumors

Greater benefit with temozolomide, bevacizumab for patients with pancreatic versus carcinoid NETs.

Adding chemotherapy to surgery prolonged life in some lung, neuroendocrine cases

Perioperative chemotherapy may benefit persons with resected small-cell lung cancer (SCLC) or large-cell neuroendocrine carcinomas (LCNECs).

Everolimus combination improved progression-free survival in neuroendocrine tumors

Progression-free survival improved in patients with advanced neuroendocrine tumors when everolimus rather than placebo was used in combination with octreotide long-acting repeatable.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs